arigo is proud to announce that our RIP1 pSer166 antibody (ARG66476) was referenced by Wu et al. for elucidating necroptosis in human HCC, recently. This antibody was also used by Tao et al. and Wang et al. for studying RIP1-contributed pathogenesis of NASH in high-fat diet feeding mice and RIP1-mediated neuroinflammation in mice, respectively.
RIP1 is a multitasking kinase with distinct functions in regulating apoptosis, necroptosis, and inflammation. The phosphorylation at Ser166 is applied as the biomarker of RIP1 kinase activity. For cell death regulation, activation of RIP1 kinase promotes apoptotic or necrotic death in the presence or absence of caspase-8, respectively. It is known that RIP1-mediated necroptosis triggers inflammation. Besides, RIP1 kinase activity has been reported to play a critical role in the pathogenesis of multiple inflammatory diseases, turning RIP1 into a promising therapeutic target for these inflammatory disorders.
arigo's RIP1 pSer166 antibody specifically recognizes activated RIP1 in human, mouse, and rat samples. It is the best solution to investigate the roles of RIP1 in cell death regulation and the physical and pathological processes in inflammatory diseases.